



## REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

September 27, 2022 07:05 AM EDT

ROCKVILLE, Md., Sept. 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present in a fireside chat at Chardan's 6th Annual Genetic Medicines Conference on Tuesday, October 4th, 2022:

### Chardan's 6<sup>th</sup> Annual Genetic Medicines Conference

**Date:** Tuesday, October 4<sup>th</sup>, 2022

**Fireside chat:** 1:30 p.m. ET

**Location:** Westin Grand Central, New York, NY

A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.

## About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

### Contacts:

Dana Cormack

Corporate Communications

[dcormack@regenxbio.com](mailto:dcormack@regenxbio.com)

### Investors:

Chris Brinzey, ICR Westwicke

339-970-2843

[chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-chardans-6th-annual-genetic-medicines-conference-301633825.html>

SOURCE REGENXBIO Inc.